Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — Investor Presentation (April 2025)
25 slides from Jade Biosciences's investor presentation, April 2025
Slide 1: Company Overview
Company Overview April 2025 NASDAQ: JBIO
Slide 2: Disclaimers
Disclaimers Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities
Slide 3: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Current funding through 2027, well-beyond biomarker-rich JADE-001 healthy volunteer data Planned Planned Interim FIH Potential MOA Program Discovery IND-enabling Clinical FIH Data Indications anti-APRIL JADE-00
Slide 4: JADE-001: a potentially best-in-class anti-APRIL mAb for IgAN
JADE-001: a potentially best-in-class anti-APRIL mAb for IgAN 4
Slide 5: Jade is developing a potentially best-in-class anti-APRIL mAb
Jade is developing a potentially best-in-class anti-APRIL mAb Estimated Current treatments do not adequately Anti-APRIL Mechanism has potential to be disease $10B+ address the need for long-term disease- modifying therapy in class poised to be frontline treatment modifying, reducing pathogenic IgA a
Slide 6: ~169K+ IgAN patients in the U.S. representing potential $10B+ market
~169K+ IgAN patients in the U.S. with majority requiring treatment*, representing potential $10B+ market IgAN patients with persistent proteinuria are ~1M+ global patients, at risk of kidney failure significant potential ex-U.S. market potential IgAN is an autoimmune kidney disease, typically diagno
Slide 7: Proposed updates to KDIGO guidelines support the frontline potential of the anti-APRIL class in IgAN
Proposed updates to KDIGO guidelines support the frontline therapeutic potential of the anti-APRIL class in IgAN IgAN patients at risk Expanding Patient Population of progressive kidney function loss • Kidney biopsy recommended in all adults with proteinuria ≥0.5 g/d where IgAN is a possible diagnos
Slide 8: Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach for IgAN
Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach for IgAN Broad B-cell depletion is ineffective in IgAN… …while targeted plasma cell modulation is highly effective. • B-cell depletion with rituximab (anti-CD20) failed to reduce Gd- • APRIL and dual APRIL
Slide 9: Selectively targeting APRIL potentially provides disease modification without BAFF inhibition immunosuppression
Selectively targeting APRIL potentially provides disease modification without added immunosuppression of BAFF inhibition APRIL is the plasma cell survival factor critically linked Targeting APRIL selectively modulates plasma to IgAN pathogenesis and disease activity cells, maintaining pool of mature
Slide 10: Reductions in proteinuria and IgA indicate APRIL inhibition drives TACI-Fc efficacy
Reductions in proteinuria and IgA in IgAN clinical studies indicate APRIL inhibition is the driving force behind TACI-Fc efficacy 10 0 Weeks 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Δ from Baseline (%) -10 Blisibimod (anti-BAFF) 24h UPCR -20 Sibeprenlimab (anti-APRIL, 8 mg/kg) -30 Sibeprenlimab (anti-
Slide 11: No clinical evidence that inhibiting BAFF provides additional efficacy beyond APRIL alone in IgAN
No clinical evidence that inhibiting BAFF provides additional efficacy beyond APRIL alone in IgAN Sibeprenlimab Zigakibart Atacicept Povetacicept MoA anti-APRIL anti-APRIL TACI-Fc Engineered TACI-Fc Status P3 P3 P3 P3 IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR Δ from baselin
Slide 12: BAFF inhibition is accompanied by the potential for significant long-term B cell depletion
BAFF inhibition is accompanied by the potential for significant long-term B cell depletion Long-term BAFF inhibition significantly depletes … whereas chronic APRIL inhibition does not impact all B cell populations… circulating lymphocytes 109/L ~7-year belimumab data in SLE shows continuous BAFF inh
Slide 13: Deeper APRIL suppression drives superior clinical efficacy
Deeper APRIL suppression drives superior clinical efficacy • Highest rates of clinical remission (proteinuria <0.3 g/day) for sibeprenlimab was accompanied by the deepest levels of APRIL suppression. • Safety profile consistent across dose levels, with no increase in overall infections. fAPRIL • Pot
Slide 14: Sibeprenlimab is potentially under-dosed in ongoing Phase 3 trial
Sibeprenlimab is potentially under-dosed in ongoing Phase 3 trial Other anti-APRILs do not inhibit APRIL fully through the dosing interval • Sibeprenlimab dosed as a single 400mg SC injection Q4W in ongoing global Phase 3 VISIONARY trial. • 400 mg SC Q4W equates to ~3.5 mg/kg IV for average Placebo
Slide 15: Potentially best-in-class profile of JADE-001
Potentially best-in-class profile of JADE-001 Femtomolar APRIL Affinity + Half Life Extension Potentially best-in-class Infrequent Q8W+ dosing Avoids unnecessary efficacy immunosuppression APRIL inhibitors demonstrate Minimizes burden in a typically Selectively targeting APRIL provides greater prote
Slide 16: Potentially best-in-class properties of JADE-001
Potentially best-in-class properties of JADE-001 Ultra-high (fM) APRIL binding Novel IP for composition affinity of matter into mid-2040s • Binds APRIL to neutralize activity • Greater APRIL binding affinity than sibeprenlimab, zigakibart, povetacicept and atacicept De novo antibody discovery Half-l
Slide 17: JADE-001 has femtomolar affinity and a slow off-rate superior to other anti-APRILs
JADE-001 has femtomolar affinity and a slow off-rate that is superior to other anti-APRILs currently in development APRIL affinity by SPR is highly predictive of in vivo APRIL affinity by SPR is highly predictive of potency to lower serum IgA in humans in vivo potency to lower serum IgA in humans 10
Slide 18: JADE-001 exhibits a highly differentiated NHP PK/PD profile from sibeprenlimab
JADE-001 exhibits a highly differentiated NHP PK/PD profile from sibeprenlimab >3X increased half-life compared to sibeprenlimab in NHPs … which is accompanied by deep and prolonged IgA coupled with successful mitigation of TMDD … reduction in NHPs following a single, saturating dose PHARMACOKINETIC
Slide 19: Anticipated 1H26 HV data potentially positions JADE-001 for accelerated development
PK, fAPRIL and IgA HV data expected in 1H 2026 Anticipated 1H26 HV data potentially positions and will define the dose and schedule designed to JADE-001 for accelerated development fully suppress fAPRIL throughout the dosing interval in IgAN patients. MOA Program IND Enabling Phase 1 Initiation Inte
Slide 20: Biomarker-rich, directly translational HV data supports potential to accelerate clinical development
Biomarker-rich, directly translational HV data supports the potential to accelerate clinical development IgA reduction in HVs is highly correlated with IgA …and early IgA reduction further correlates with W36 reduction in IgAN patients at multiple time points… UPCR reduction, the endpoint for accele
Slide 21: Pipeline beyond JADE-001
Pipeline beyond JADE-001 21
Slide 22: Additional Jade programs expected to focus on best-in-class product profiles in high-value autoimmune indications
Additional Jade programs expected to focus on best-in-class product profiles in high-value autoimmune indications Autoimmune Potentially best- Potential rapid Limited Jade team indications with in-class and path to clinical competition expertise significant best-in- PoC expected market indication op
Slide 23: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Current funding through 2027, well-beyond biomarker-rich JADE-001 healthy volunteer data Planned Planned Interim FIH Potential MOA Program Discovery IND-enabling Clinical FIH Data Indications anti-APRIL JADE-00
Slide 24: Capitalization following close of merger with Aerovate
Capitalization following close $49.9M cash as of March 31, 2025 of merger with Aerovate +$192.7M net proceeds from PIPE on April 28, 2025 Number of Shares Common stock Shares outstanding 32,235,927 Preferred stock (as converted to 12,622,000 Common stock equivalents common stock) Pre-funded warrants
Slide 25: Thank you
Thank you www.JadeBiosciences.com | info@jadebiosciences.com NASDAQ: JBIO
Jade Biosciences — Investor Presentation (April 2025) on 6ix